KENILWORTH (NJ) (dpa-AFX) - Merck (MRK) announced the completion of the
acquisition of Harpoon Therapeutics, Inc. (HARP). Harpoon is now a wholly-owned
subsidiary of the company. Harpoon's common stock will no longer be publicly
traded or listed on the Nasdaq Stock Market. The impact of the transaction on
expected full-year non-GAAP EPS is approximately $0.26 per share, which was
included in full-year 2024 financial outlook issued on February 1, 2024.

Harpoon's lead candidate, MK-6070, is a T-cell engager targeting delta-like
ligand 3, an inhibitory canonical Notch ligand that is expressed at high levels
in small cell lung cancer and neuroendocrine tumors.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX